Skip to main content

Search form

Search

About the Department
Divisions
Faculty
- Distinguished Faculty
- Faculty Development
Patient Care
- Referrals
- In the Community
Research
Education and Training
MedicineNews

About the Department
Divisions
Faculty
- Distinguished Faculty
- Faculty Development
Patient Care
- Referrals
- In the Community
Research
Education and Training
MedicineNews

Home
Divisions
Hematologic Malignancies and Cellular Therapy
Research
Clinical Research

Hematologic Malignancies and Cellular Therapy

Clinical Research

Learn About Our Clinical Trials

BMT and Cellular Therapies
Leukemia and Multiple Myeloma
Lymphomas - Non-Hodgkins Lymphoma and Hodgkins Lymphoma

About
Faculty
Patient Care
Education and Training
Research
Division Events
Division News

Recent Articles

Call for applications: Duke UNC-Chapel Hill Immunotherapy Training Grant

13 Medicine faculty recognized by the School of Medicine

Sullivan named 2020 recipient of the ASTCT Lifetime Achievement Award

Bartlett receives 2020 ASH Scholar Award

8 faculty from Medicine selected for the 2020 Duke Clinical Leadership Program

Recent publications by our faculty

Treatment Journeys of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The Connect MM Registry.

Clin Lymphoma Myeloma Leuk

A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535).

Blood Adv

A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535).

Blood Adv

View all our publications

Quick Links

Diversity
Careers
Giving
About Duke and Durham

Twitter Instagram RSS

medschool.duke.edu
duke.edu
dukehealth.org

Copyright 2004-2019 Duke University and Duke University Health System, All rights reserved